Tel Aviv, Israel-based Aidoc Ltd. has received the green light from the U.S. FDA for its pulmonary embolism (PE) product in its suite of artificial intelligence (AI)-based workflow orchestration solutions. Its latest offering aims to help radiologists flag and triage PE cases in chest CTs. The company is looking to cut the time from scan to diagnosis, which could mean for some patients a result in less than five minutes vs. hours – thereby speeding up treatment and improving prognosis.